TITLE

Identification of Authentic Inhibitors of HIV-1 Integration

AUTHOR(S)
Witvrouw, M.; Fikkert, V.; Vercammen, J.; Van Maele, B.; Engelborghs, Y.; Debyser, Z.
PUB. DATE
April 2005
SOURCE
Current Medicinal Chemistry - Anti-Infective Agents;Apr2005, Vol. 4 Issue 2, p153
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Current strategies for the treatment of human immunodeficiency virus (HIV) infection are based on cocktails of drugs that target the viral entry step and the enzymes reverse transcriptase or protease. At present, the clinical benefit of this combination therapy for HIV-infected patients is considerable, although it is not clear how long this effect will last taking into account the emergence of multiple drug-resistant viral strains. Addition of new anti-HIV drugs targeting additional steps of the viral replication cycle may increase the potency of inhibition and prevent significant resistance development. During HIV replication, integration of the viral genome into the cellular chromosome is an essential step catalyzed by the viral integrase. Although HIV integrase is an attractive target for antiviral therapy and the focus of intensive research, to date only two classes of compounds that selectively inhibit HIV integration have been identified, namely the diketo acids and the pyranodipyrimidines. In this review we address the question why it has proven so difficult to find potent and selective integrase inhibitors; we point to potential pitfalls in defining an inhibitor as an authentic integrase inhibitor and we propose new strategies and new technologies for the discovery of genuine HIV integration inhibitors. For the diketo acids and the pyranodipyrimidines we will discuss in detail the antiviral activity, the molecular mechanism of anti-HIV action, the in vitro HIV resistance development and the clinical perspectives.
ACCESSION #
16595821

 

Related Articles

  • Ongoing HIV dissemination during HAART. Grossman, Zvi; Polis, Michael; Feinberg, Mark B.; Grossman, Zehava; Levi, Itschak; Jankelevich, Shirley; Yarchoan, Robert; Boon, Jacob; de Wolf, Frank; Lange, Joep M.A.; Goudsmit, Jaap; Dimitrov, Dimiter S.; Paul, William E. // Nature Medicine;Oct1999, Vol. 5 Issue 10, p1099 

    Examines a model of HIV replication which occurs in multiple local bursts. Association with immune activation in response to antigens; Effects of anti-retroviral drugs on the size of the bursts; Implications for HIV treatment.

  • Disruption of Type I Interferon Induction by HIV Infection of T Cells. Sanchez, David Jesse; Jr.Miranda, Daniel; Marsden, Matthew D.; Dizon, Thomas Michael A.; Bontemps, Johnny R.; Davila, Sergio J.; Del Mundo, Lara E.; Ha, Thai; Senaati, Ashkon; Zack, Jerome A.; Cheng, Genhong // PLoS ONE;9/16/2015, Vol. 10 Issue 9, p1 

    Our main objective of this study was to determine how Human Immunodeficiency Virus (HIV) avoids induction of the antiviral Type I Interferon (IFN) system. To limit viral infection, the innate immune system produces important antiviral cytokines such as the IFN. IFN set up a critical roadblock to...

  • A Phase 1b/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection. Wilkinson, John; Ewart, Gary; Luscombe, Carolyn; McBride, Kristin; Ratanasuwan, Winai; Miller, Michelle; Murphy, Robert L. // Journal of Antimicrobial Chemotherapy (JAC);Mar2016, Vol. 71 Issue 3, p731 

    Objectives: BIT225 (N-carbamimidoyl-5-(1-methyl-1H-pyrazol-4-yl)-2-naphthamide), a novel acyl-guanidine, is a novel antiviral drug that blocks Vpu ion channel activity and has anti-HIV-1 activity in vitro. The antiviral effect of BIT225 is most pronounced in cells of the myeloid...

  • Nucleoside-Free Boosted Double PI Regimen: Significant CD4+ T-Cell Recovery in Patients with Poor Immunologic Response Despite Virologic Suppression. Lehmann, Clara; Jung, Norma; Hofmann, Anika; Cornely, Oliver A.; Wyen, Christoph; Fätkenheuer, Gerd; Hartmann, Pia // Current HIV Research;Nov2008, Vol. 6 Issue 6, p555 

    Antiretroviral therapy in human immunodeficiency virus infection is occasionally associated with poor immunologic responses despite full suppression of viral replication. As some combinations of nucleoside analogues (NA) have been associated with paradoxical depletion of CD4+ T- cells, we...

  • The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Ramratnam, Bharat; Mittler, John E.; Zhang, Linqi; Boden, Daniel; Hurley, Arlene; Fang, Fang; Macken, Catherine A.; Perelson, Alan S.; Markowitz, Martin; Ho, David D. // Nature Medicine;Jan2000, Vol. 6 Issue 1, p82 

    Replication-competent HIV-1 can be isolated from infected patients despite prolonged plasma virus suppression by anti-retroviral treatment. Recent studies have identified resting, memory CD4[sup +] T lymphocytes as a long-lived latent reservoir of HIV-1 (refs. 4,5). Cross-sectional analyses...

  • Choosing CCR5 or Rev siRNA in HIV-1. Arteaga, H. Jose; Hinkula, Jorma; van Dijk-Hard, Iris; Dilber, M. Sirac; Wahren, Britta; Christensson, Birger; Mohamed, Abdalla J.; Edvard Smith, C. I. // Nature Biotechnology;Mar2003, Vol. 21 Issue 3, p230 

    Reacts to reports in 'Nature Biotechnology' and in 'Nature' that demonstrate that small inhibitory RNAs (siRNAs) efficiently target and degrade human immunodeficiency virus (HIV)-1 RNA sequences and inhibit viral replication. Reactors' view that treatments limited to the inhibition of viral...

  • A New HIV-1 Group. Delwart, Eric; Smith, Jeanette M. // JAMA: Journal of the American Medical Association;12/9/98, Vol. 280 Issue 22, p1960 

    Discusses the identification of a human immunodeficiency virus type 1 distinct from group M and group O. Epidemiological study of HIV-1 diversity in Cameroon; Practical implications regarding the efficacy of antiviral drugs, future vaccines, viral load tests and more; Impact of new strategies...

  • Human Immunodeficiency Virus--1 RNA Levels in Cerebrospinal Fluid Exhibit a Set Point in Clinically Stable Patients Not Receiving Antiretroviral Therapy. Ellis, Ronald J.; Childers, Meredith E.; Zimmerman, Joshua D.; Frost, Simon D.W.; Deutsch, Reena; McCutchman, J. Allen // Journal of Infectious Diseases;6/1/2003, Vol. 187 Issue 11, p1818 

    To characterize, over time, cerebrospinal fluid (CSF) virus-load change in clinically stable patients, human immunodeficiency virus (HIV)-1 RNA levels were measured in serial CSF samples and in plasma samples obtained, during periods of 20 days-6 years, from 17 HIV-infected individuals not...

  • Response-Guided Boceprevir-based Triple Therapy in HIV/HCV-coinfected Patients: The HIVCOBOC-RGT Study. Mandorfer, Mattias; Steiner, Sebastian; Schwabl, Philipp; Payer, Berit A.; Aichelburg, Maximilian C.; Lang, Gerold; Grabmeier-Pfistershammer, Katharina; Trauner, Michael; Peck-Radosavljevic, Markus; Reiberger, Thomas // Journal of Infectious Diseases;Mar2015, Vol. 211 Issue 5, p729 

    Background. The HIVCOBOC-RGT study (NCT01925183) was the first study to evaluate response-guided shortening of the duration of boceprevir (BOC)-based triple therapy in human immunodeficiency virus (HIV)/hepatitis C virus genotype 1-coinfected patients (HIV/HCV-GT1).Methods. After 4 weeks of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics